share_log

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases

《生物技术日报》:对阿卡迪亚的抗精神病药物不屑一顾,Akebia 未能通过 COVID-19 研究,Kazia 的脑转移数据令人鼓舞
Benzinga Real-time News ·  2022/08/05 11:36
Here's a roundup of top developments in the biotech space over the last 24 hours:
以下是过去24小时生物技术领域的热门发展综述:
Stocks In Focus
关注的股票
FDA Signs Off Marker Therapeutics Cell Therapy Study In Lymphoma Setting
FDA批准MARKER治疗淋巴瘤的细胞治疗研究
The FDA cleared Marker Therapeutics Inc's (NASDAQ:MRKR) Investigational New Drug (IND) application for MT-601 for relapsed/refractory non-Hodgkin lymphoma who have failed or are ineligible to receive anti-CD19 CAR T cell treatment.
FDA批准了标记物治疗公司纳斯达克代码:MRKR)MT-601的研究性新药申请,用于治疗未能或没有资格接受抗CD19CAR T细胞治疗的复发性/难治性非霍奇金淋巴瘤。
MT-601 is a multi-tumor-associated antigen (multiTAA)-specific T cell product targeting six antigens.
MT-601是一种针对六种抗原的多肿瘤相关抗原(MultiTAA)特异性T细胞产物。
In addition, the FDA has cleared Marker to initiate its study at a dose level of 200 million cells per infusion versus...
此外,FDA已经批准Marker启动其研究...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发